Chimeric Therapeutics (ASX: $CHM) Phase 1B ADVENT-AML Trial Update

Chimeric Therapeutics (ASX: $CHM) has announced the advancement of the Phase 1B ADVENT-AML trial of CHM CORE-NK to the next planned cohort. The trial, which is the first to evaluate the synergy of NK cell therapy in combination with the current standard of care for acute myeloid leukemia (AML), has shown promising results in the initial cohort, with no dose-limiting toxicities reported.

Executive Commentary on ADVENT-AML Trial Progression

It has been great to see the progress of this clinical trial for these AML patients. The Phase 1B ADVENT-AML trial of CHM CORE-NK has shown encouraging results in the initial cohort, paving the way for the advancement to the next cohort. We are committed to bringing the promise of cell therapy to life for more patients with cancer and are optimistic about the potential of this innovative treatment approach. - Dr Rebecca McQualter, Chief Operating Officer of Chimeric

Summary of CHM CORE-NK Trial Advancement

Chimeric Therapeutics (ASX: $CHM) has announced the advancement of the Phase 1B ADVENT-AML trial of CHM CORE-NK to the next planned cohort. The trial, which aims to evaluate the synergy of NK cell therapy in combination with the current standard of care for AML, has progressed based on the positive results from the initial cohort. With no dose-limiting toxicities reported, the safety monitoring committee has authorized the trial to advance to the next cohort, testing a higher dose of CHM CORE-NK in combination with the standard-of-care treatment. Chimeric Therapeutics remains focused on bringing the promise of cell therapy to life for more cancer patients and is actively working on the development and commercialization of innovative cell therapies across multiple disease areas in oncology.